Hypoxia-inducible factor 1 (HIF-1) controls angiogenesis and glycolysis, two leading characteristics of solid tumor invasion, metastasis, and lethality. Increased angiogenesis is also found in the bone marrow (BM) of leukemias. Less is known in leukemia about the role of HIF-1 and vascular endothelial growth factor (VEGF), the most important proangiogenic target gene of HIF-1. We show by immunohistochemistry that the oxygen-regulated component of HIF-1 (HIF-1a) is overexpressed in clusters of leukemic cells in BM specimens of childhood acute lymphoblastic leukemia (ALL) and absent in biopsies of normal BM. Half the HIF-1a-positive ALL biopsies exhibited VEGF coexpression. Among 96 children with relapsed ALL, diagnostic BM aspirates with high VEGF mRNA levels were associated with a significantly lower probability of eventfree survival at 3 years (0.3170.08 vs 0.6570.07, P ¼ 0.003). Those with poor molecular response to therapy (evaluated by MRD assessment) had 2.2-fold higher VEGF levels than those responding well to chemotherapy (P ¼ 0.005). In conclusion, the data demonstrate activation of the HIF pathway in the BM of ALL patients and indicate that the expression of HIF target genes, such as VEGF, play an important role in leukemia progression, therapy response, and outcome.
Introduction
Angiogenesis depends on the expression of specific mediators that initiate the cascade of events leading to the formation of new microvessels. 1 Among these, vascular endothelial growth factor (VEGF) type A plays a pivotal role in the induction of neovascularization in solid tumors. 2 For viability and growth of solid tumors, angiogenesis is known to be an absolute requirement. 3 In the pathophysiology of hematologic malignancies emerging data also suggest a crucial role of VEGF and angiogenesis. 4 Increased microvessel density has been documented in the bone marrow (BM) of patients with hematologic malignancies including ALL. [5] [6] [7] Cellular VEGF levels were found to be an independent predictor of outcome in acute myeloid leukemia (AML) 8 as well as in chronic myeloid leukemia (CML). 9 In contrast to AML in adults, there is inconsistent evidence regarding the relation of VEGF levels and survival in pediatric AML. 10, 11 However, it was suggested recently that VEGF may play an important role in the pathophysiology of childhood ALL. 12 Intratumoral hypoxia has been found to be a key event in triggering angiogenesis in solid tumors mediated by hypoxiainducible factors (HIF). 13 The HIF transcriptional complex is a heterodimer consisting of an a-subunit (HIF-1a, HIF-2a, or HIF3a) and a b-subunit (HIF-1b) called arylhydrocarbon receptor nuclear translocator (ARNT).
14 While the ARNT subunit is not affected by hypoxia, HIF-1a and HIF-2a proteins accumulate rapidly under hypoxic conditions, thereby activating the expression of numerous target genes involved in erythropoiesis, angiogenesis, and energy metabolism. 15 In contrast to the well-investigated mechanisms leading to angiogenesis in solid tumors, less is known about the factors contributing to increased microvessel density in the BM of hematologic malignancies. Normal hematopoiesis occurs under relatively hypoxic conditions in the BM. 16 The reported mean pO 2 in healthy BM is approximately 52 mmHg. 17 Its spatial variation has not been precisely defined, but is probably quite significant. 18, 19 Hypoxic regions typically located away from the blood sinus are crucial in the proliferation and differentiation of all hematopoietic cells. 20 More recent reports identified in chimera experiments with HIF-1a/Rag2-null mice an important role for HIF-1a in B-lymphocytes development 21 and the loss of HIF-2a resulted in pancytopenia. 16 Hematopoietic differentiation assays with ARNT/HIF-1b, the obligate dimerization partner for HIF-1a and -2a, null embryoid bodies suggest VEGF deficiency as a cause for the hematopoietic defects. 22 In order to increase the understanding of the role of the HIF system in the biology of ALL, we studied the expression of HIF1a, VEGF, VEGFR1, VEGFR2, and Ki67 in BM iliac core biopsies from 37 children with newly diagnosed, untreated malignancies, including 18 ALL, nine neuroblastoma with BM metastasis, and 10 malignancies not involving the BM. Additionally, we performed an intraindividual comparison of the absolute VEGF mRNA expression in BM aspirates between diagnosis and relapse of B-cell precursor (BCP)-ALL. Finally, we investigated the VEGF mRNA expression in 96 diagnostic BM aspirates from children with first relapse of BCP-ALL, enrolled into ALL-REZ BFM (ALL-Relapse trials of the Berlin Frankfurt Muenster study group), to evaluate if VEGF mRNA expression is associated with poor prognosis.
Materials and methods

Patients and samples
Immunostaining of HIF-1a, VEGF, VEGFR1 and VEGFR2: BM iliac crest trephine (core) biopsies from 37 children with newly diagnosed, untreated malignancies were studied, including 18 ALL, nine neuroblastoma with BM metastasis, and 10 normal biopsies. Diagnosis was established by morphology, immunophenotyping and cytogenetic analysis. Table 1. VEGF mRNA expression analysis: VEGF expression was determined retrospectively in diagnostic BM samples (containing at least 75% blasts before Ficoll separation) collected prior to treatment from 96 children with first relapse of BCP-ALL, enrolled into ALL-REZ BFM 96 during 1998 and 2001. 23, 24 In seven cases, BM samples were available from both first relapse of BCP-ALL and initial ALL (blast count 475%). After density gradient centrifugation, mononuclear cells were cryopreserved in liquid nitrogen until analysis. Analyses were focused on BCP-ALL, because (i) BCP-ALL comprises the majority of ALL in childhood (85%) and (ii) since 1998 MRD status is prospectively assessed for all patients with intermediate prognosis in the relapse trials ALL-REZ BFM (intermediate strategic group, 60% of all BCP-ALL). 25 For definitions see below. Thus, we used all available BM aspirates from children with first relapse of BCP-ALL enrolled into ALL-REZ BFM 96 since 1998, containing at least 75% BM blasts (before Ficoll separation) and high RNA quality after extraction. Comparison of patient characteristics of the studied (n ¼ 96) and the overall BCP-ALL population of the indicated time period (n ¼ 323) enrolled into this trial did not disclose any significant differences regarding gender, time of relapse, site of relapse (BM isolated or combined), PBC, immunophenotype (pro-B-, common-and pre-B-ALL), BCR/ ABL and TEL/AML1 fusion transcripts. The protocol ALL-REZ BFM 1996 is a prospective, controlled, randomized, multicenter study to optimize treatment of children with relapsed ALL with about 100 participating centers. 23, 24 The design is based on experience from four preceding trials of the ALL-REZ BFM Study Group since 1983. Central elements are short intensive multidrug chemotherapy courses, followed by cranial irradiation and maintenance therapy. A series of risk factors allow to define patients with an acceptable prognosis after chemotherapy and those, who need further intensification by stem-cell transplantation (SCT), for definitions see below. The ALL-REZ BFM 96 study was approved by the institutional review board of the Humboldt-University at Berlin and informed consent for treatment and accompanying scientific studies was obtained from the parents.
Immunohistochemistry
Immediately after BM biopsy, samples were fixed in 4% formaldehyde, decalcified with EDTA, and embedded in paraffin. Serial 4 mm thick sections were cut of each sample and placed on 3-aminopropyl-tri-ethoxysilane coated slides. For immunohistochemical staining, sections were dewaxed in xylene and rehydrated. Negative controls were included by omission of the primary antibody and were consistently negative. Tissues from renal clear cell carcinomas harboring mutations in the von Hippel Lindau (VHL) gene leading to constitutive overexpression of HIF-1a served as positive controls. 26 After immunohistochemistry, the sections were coverslipped and signals were analyzed with a Leica DMRB microscope (Leica, Bensheim, Germany), using differential interference contrast. Photographs were digitally recorded by means of a Visitron system (Visitron, Puchheim, Germany).
HIF-1a:
Immunohistochemical staining was performed as described in detail previously. 27 HIF-1a was detected by a mouse antihuman HIF-1a monoclonal antibody (a67, 1:10,000; Novus Biologicals, Littleton, CO, USA). For antigen retrieval, slides were cooked for 6.5 min in target retrieval solution (Dako, Hamburg, Germany) by using a pressure cooker. A catalyzed signal amplification kit based on a streptavidin-biotin-peroxidase reaction (CSA; Dako) was employed for visualization according to the manufacturer's instructions. Diamino-benzidine (DAB) was used as a chromogen. Double-label immunohistochemistry was performed for HIF-1a and either CD3 (T-cell marker) or CD20 (B-cell marker; mouse antihuman monoclonal antibodies, working dilutions 1:100, both Dako). First, HIF-1a was detected as described above, but instead of the final peroxidase reaction a Texas-red labeled anti-biotin antibody was used. Then slides were blocked with 5% skim milk in PBS, washed and CD3 or CD20 were detected by anti-mouse Cy2-labeled antibodies.
VEGF, VEGFR1, VEGFR2, and Ki67: Immunohistochemical staining was performed by the alkaline phosphatase/ antialkaline phosphatase double bridge technique (Dako-APAAP Kit; Dako). The following monoclonal antibodies were used: VEGF (working dilution 1:5; Dianova, Hamburg, Germany); VEGFR1 and VEGFR2 (working dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA); Ki67 (working dilution 1:40; Dianova). Antigen retrieval was achieved by pressure cooking in 50 mM Tris/0.2 mM EDTA pH 9.0 buffer for 3 min. The primary antibodies were applied overnight at 41C. Subsequent steps were performed according to the manufacturer's instructions. Nuclei were finally counterstained with hematoxylin.
RNA extraction, cDNA preparation and quantitative real-time PCR Total RNA was extracted using QIAgen RNeasy Mini Kit with DNase on column digest (Qiagen, Hilden, Germany). Highquality RNA as determined by photometric analysis and gel electrophoresis was subjected to reverse transcription using the Table 1 Clinical data of patients enrolled in the immunohistochemical study 
HIF-1a and VEGF in childhood ALL S Wellmann et al
ThermoscriptKit and the supplied Oligo-dt primer (Invitrogen, Karlsruhe, Germany). A volume of 1 ml first-strand cDNA was subsequently used for real-time PCR quantification by LightCycler technology (Roche Diagnostics, Mannheim, Germany). All different VEGF mRNA variants were quantified simultaneously with consensus primers as described previously. 28 The generally accepted method to correct for sample-tosample variation in RT-PCR approaches is to amplify a cellular RNA that serves as an internal reference simultaneously with the target RNA. 29 Here we used RPL13A, also known as ribosomal highly basic 23-kDa protein, because ribosomal proteins showed the lowest interindividual variability of several tested reference genes in a comprehensive analyses of different leukemias. 30 To confirm this finding, we analyzed the recently published microarray data set of 360 investigated childhood ALL samples available at http://www.stjuderesearch.org/data/ALL1/ . 31 Expression levels of 12625 transcripts have been measured using the Affymetrix HG-U95Av2 microchip. Given that constant high expression is desirable for reference genes, we used variance divided by mean expression as criterion to be minimized for reference genes. According to this criterion, we found RPL13A among the top six of all genes measured beside elongation factor 1-alpha (PTI-1), elongation factor EF-1-alpha, two uncharacterized cDNA sequences (Accession Numbers AI541542 and AI557852) and the human homologue mRNA to yeast ribosomal protein L41. Thus, we believe that RPL13A is a well-suited internal reference gene for analyis in ALL. To determine the absolute number of target transcripts, calibration curves were generated from cloned plasmid cDNAs for VEGF and RPL13A.
For each sample, VEGF and RPL13A mRNA were measured simultaneously and in triplicate in the same LightCycler run, together with the calibration curves. Quantitation was carried out automatically by the LightCycler software 3.3 in the second derivative maximum mode. Quantitative results are presented as copies of target cDNA per 1000 copies of RPL13A cDNA.
Definitions: Risk stratification in the ALL-REZ BFM 96 study: 23, 24 Intermediate risk: late (430 months after initial diagnosis) isolated and combined BM relapse and early (18-30 months) combined relapse of a BCP-ALL. High risk: early isolated or very early (o18 months) isolated and combined BM relapse of a BCP-ALL, or any BM relapse of a T-cell ALL. Minimal residual disease (MRD): MRD negative: 1 leukemic cell in 41000 normal mononuclear cells, MRD positive: 1 leukemic cell in p1000 in BM aspiration at day 42 after diagnosis. 25 Statistical analysis: Statistical analysis entailed Pearson's (product-moment) correlation, Mann-Whitney U-test, KruskalWallis test, Fisher's exact test and Pearson w 2 -test. The level of significance was set to p0.05. Event-free survival (EFS) data were determined by the Kaplan-Meier method, and differences between survival curves were calculated using the log-rank test. EFS was computed from the date of remission to the date of analysis or the date of an adverse event. In case of nonresponse to therapy or death during induction, EFS was set to 0. The relative risk of EFS was calculated by univariate and multivariate analyses using Cox regression analysis. Computations were performed using the SPSS for Windows software, version 11.0 (SPSS Inc., Chicago, USA).
Results
Expression of VEGF and its receptors VEGFR1 and VEGFR2 as well as its main transcription factor HIF-1a was evaluated by immunohistochemical staining in BM core biopsies of 18 children with ALL at presentation. Results from these ALL patients were compared with the degree of protein expression in BM biopsies obtained at diagnosis from nine children with BM metastasis of neuroblastoma and 10 with different diseases but with normal BM morphology. Clinical data, including hemoglobin and hematocrit levels, of all patients (n ¼ 37) are depicted in Table 1 . Almost all ALL patients had reduced hemoglobin and hematocrit levels compared to controls, as a typical sign of leukemia (hemoglobin, 7.8 (4.7-12.3) vs 11.85 (6.4-14.4) g/dl; hematocrit (24% (20.1-36.5) vs 33.5% (18.8-44) ).
Of the 18 ALL specimens, 12 showed HIF-1a immunoreactivity, two of them strong (450% total cells), six moderate (o50%), and four weak (o10%) ( Table 2 ). In all ALL specimens HIF-1a immunostaining was concentrated primarily within the nuclei of leukemic cells. These findings were proven by doublelabel fluorescence immunohistochemistry for HIF-1a and either CD3 (T-ALL) or CD20 (BCP-ALL) (Figure 1) . In ALL patients with moderate to strong HIF-1a immunoreactivity (n ¼ 8), the HIF-1a-positive leukemic cells were located predominantly in clusters (Figure 1 ). The degree of HIF-1a immunoreactivity in ALL did not correlate with hemoglobin, hematocrit and BM blast cell count (r ¼ À0.108, P ¼ 0.702; r ¼ À0.045, P ¼ 0.875, and r ¼ 0.032, P ¼ 0.899 respectively), indicating that systemic anemia is not the cause of HIF-1a accumulation in the BM. For better evaluation of the findings in ALL BM specimens especially with regard to HIF-1a staining, we included in our study nine BM specimens of neuroblastoma BM metastases. Of nine neuroblastoma, 7 exhibited weak to strong staining for HIF1a. In contrast, HIF-1a expression was not detected in neither of 10 nonmalignant BM specimens.
Staining for Ki67 revealed in the ALL samples on average slightly more Ki67 positive cells, 60% (range 35-90), than in the control samples, 55% . Interestingly, comparison of the degree of HIF-1a immunoreactivity with the percentage of Ki67 positive cells in ALL showed a correlation (r ¼ 0.561, P ¼ 0.015), suggesting that a high proliferation rate of leukemic cells in the BM of ALL promotes the local accumulation of HIF-1a.
VEGF antigen was detected in 7/18 ALL-BM specimens and in 8/9 neuroblastoma-BM specimens. Whereas the VEGF-positive ALL samples usually exhibited weak (n ¼ 4) to moderate (n ¼ 2) staining, neuroblastoma samples exhibited predominantly extensive staining. Of seven VEGF-positive ALL samples, six showed coexpression with HIF-1a, indicating that a subset of ALL are distinguished by a proangiogeneic immunophenotype. As shown in Figure 1 , VEGF signals were seen primarily in the cytoplasm of leukemic blasts and as diffuse staining in the intercellular spaces. Sporadic VEGF-positive nonleukemic cells were found in all ALL samples. These cells were found as few, isolated, or clustered elements throughout the stroma and were distinguishable from tumor cells.
BM of ALL patients stained positive for the cell membraneassociated receptor tyrosine kinases VEGFR1 and VEGFR2 with different expression patterns. VEGFR1 was consistently detected in the majority of leukemic cells in all BM specimen of ALL. In HIF-1a and VEGF in childhood ALL S Wellmann et al contrast, 13/18 ALL specimens displayed a weak to strong staining for VEGFR2 predominantly with membrane accentuation of nonleukemic cells, especially endothelial cells. Of nine neuroblastoma, eight exhibited moderate to strong staining for VEGFR1 and 6/9 moderate staining for VEGFR2.
VEGF mRNA was detectable by means of quantitative realtime RT-PCR in all BM aspirates from children with BCP-ALL. The intraindividual comparison of the absolute VEGF mRNA expression in BM aspirates between diagnosis and first relapse of BCP-ALL depicted 2.2-fold (range 1.25-4.4-fold) higher VEGF levels for relapsed ALL from seven children.
To evaluate the clinical relevance of VEGF in relapsed childhood BCP-ALL, 96 BM aspirates were analyzed. As the detected VEGF mRNA levels followed a normal curve of distribution, even when expressed as log-normal distribution according to skewness and kurtosis, the median value was used. Patients with VEGF levels above the median value (2.73) had a significantly lower probability of EFS at 3 years and a median follow-up of 2.09 years, range 0.97-6.25 years (pEFS, 0.6570.07 vs 0.3170.08, P ¼ 0.003) as estimated by KaplanMeier analysis (Figure 2) . Expression of VEGF was directly associated with clinical risk groups. High-risk patients (n ¼ 45) had significantly elevated VEGF levels compared to patients assigned to the intermediate risk group (n ¼ 51, P ¼ 0.037) ( Table 3 ). 
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No relationship between VEGF levels and other parameters including gender, age at relapse, age at initial diagnosis, peripheral blood cell count, marrow blast percentage, followup time and common translocations were observed (Table 3) . Furthermore, there was neither a relationship between VEGF levels and chemotherapy with or without stem-cell transplantation nor between VEGF levels and different front-line chemotherapeutic regimens (ALL-BFM 90/95 32 and COALL 92/ 97 33 ). Multivariate cox regression analysis revealed an independent prognostic relevance of VEGF expression (P ¼ 0.023) as well as time of relapse (Po0.001), BCR-ABL translocation (P ¼ 0.013), and peripheral blood cell count (P ¼ 0.031). Other covariates showed no independent significance (site of relapse, immunophenotype, age at relapse, age at initial diagnosis, and TEL/ AML1 translocation).
MRD status of all patients belonging to the intermediate risk group was assessed. Those with poor molecular response (MRD positive, n ¼ 26) had 2.2-fold higher VEGF mRNA levels than those responding well to chemotherapy (MRD negative, n ¼ 25, P ¼ 0.005) ( Table 3) .
Discussion
VEGF and its cellular receptors are required for tumor angiogenesis. In contrast to solid tumors, in which intratumoral hypoxia triggers the expression of VEGF via HIF-1a accumulation, less is known about the proangiogenic pathways in leukemias, especially the role of HIF-1a. Therefore, we examined BM core biopsies from 37 children with ALL at first presentation (n ¼ 18), with BM metastases of neuroblastoma (n ¼ 9), and different diseases without BM involvement (n ¼ 10) for expression of HIF-1a, VEGF, VEGF receptors and Ki67 by means of immunohistochemistry.
A major finding in this survey of malignant and normal BM specimens was the upregulation of HIF-1a protein in ALL. The increase in HIF-1a expression was substantial, such that positive nuclear staining was readily detectable in the majority of ALL and neuroblastoma specimens, whereas it was negative in normal BM. HIF-1a staining was present in clusters of leukemic cells and in some of the ALL specimens as strong as it was found in solid tumors. 34 To the best of our knowledge, there are no immunohistochemical analyses yet of HIF-1a expression in leukemia and only two in lymphoma. In one analysis of miscellaneous tumor entities, no HIF-1a expression was found in three lymphomas. 35 In the other analysis focusing on high-and low-grade lymphomas, HIF-1a was expressed weakly and in a diffuse pattern, unaffected by the presence of necrosis. 36 The only study
Figure 2
Life-table analysis of relapsed ALL patients by VEGF. Probability of EFS (at 3 years) in relation to VEGF mRNA expression for 96 patients enrolled in the relapse trial ALL-REZ BFM 96. Children with VEGF levels greater than the median have significantly worse pEFS (31% (s.e., 8%)) when compared with those with VEGF levels below the median (65%; (s.e., 7%)) (P ¼ 0.003, log-rank test). Table 3 Univariate analysis of differences by VEGF mRNA levels, included are 96 children with first relapse of BCP-ALL, enrolled into the ALL-REZ BFM 96 trial Recently, it was reported that some leukemic cell lines constitutively express HIF-1a protein under normoxic conditions. 37 Furthermore, in growth factor-dependent Ba/F3 cells the translocation t(9;22) (BCR/ABL) was found to trigger HIF-1a accumulation. 38 Considering results from mutated VHL gene in clear cell renal carcinomas, which lead to ubiquitous HIF-1a expression in almost all carcinoma cells, 26 we would expect a similar generalized HIF-1a expression pattern in our ALL samples if genetic alterations would be the reason. As no BCR-ABL-positive ALL specimens were included in our study and HIF-1a expression correlates with the proliferation rate, assessed by Ki67 staining, as it is known from solid tumor biology, 35 we conclude that rather changes in the microenvironment account for the regionally strong HIF-1a staining in leukemic cells.
In solid tumor biology, adaptation to hypoxia has serious consequences: hypoxic tumor cells acquire oncogenic alterations of metabolism, gain an increased resistance to radiotherapy and chemotherapy, and are more prone to mutations. Finally, hypoxia results in clonal expansion of cells with a more aggressive phenotype and increased metastatic potential. 39 Recently, it was reported that during progression of acute myeloid leukemia in rats increased cellular hypoxia occurs and, in contrast to normal cells, some of the leukemic cells proliferate even during hypoxia. 40, 41 Despite strong HIF-1a expression in some ALL and neuroblastoma, VEGF expression was predominantly strong only in neuroblastoma. These findings could indicate that other HIF-1 target genes than VEGF are more important in ALL. It is important to note that HIF protein is rapidly degraded within minutes in the presence of oxygen, 42 whereas the mRNA and protein kinetics underlying target gene expression are much slower.
14 Thus, dynamic changes in micro-oxygenation could well explain why the expression of HIF and VEGF protein are not entirely concordant. In fact, also in solid tumors only partial overlap has been observed between hypoxia markers, HIF protein and target gene expression. 43, 44 Previously, significantly elevated plasma levels of VEGF were found in acute and chronic leukemias as well as myelodysplastic syndromes of adults were found, except for ALL. 6 Nevertheless, the authors corroborated the finding of two other reports 5, 7 that the microvessel density in BM biopsies is highly increased in ALL of adults and children, suggesting that factors other than VEGF may be more important for the level of BM vascularity in ALL. The expression pattern of the VEGF receptors presented here in the ALL BM specimens with strong expression of VEGFR1 and differing expression intensity of VEGFR2 mainly from nonleukemic cells, is in line with reports on ALL cell lines. 45 In these cell lines, VEGFR1 was strongly expressed and VEGFR2 could not be detected by means of RT-PCR. Thus we conclude, that in ALL at first presentation the main endothelial pathway of VEGF and VEGFR2 required for tumor angiogenesis is of minor importance than, for example, in AML. 46 Nevertheless, in a subset of ALL VEGF immunoreactivity was observed and together with the strong VEGFR1 expression the pathway of VEGF and VEGFR1 could play a role in autocrine mechanisms, as it was seen in hematopoietic stem cells. 47 Yet, recently it was demonstrated that cellular VEGF mRNA levels are several-fold higher in relapsed childhood ALL compared to initial ALL. 12 This finding makes the group of relapsed ALL even more interesting to study VEGF expression by immunohistochemistry. However, as in childhood ALL BM aspirates are usually sufficient for diagnosis, core biopsies are not carried out. Therefore, BM biopsies of ALL in childhood are restricted mainly to ambiguous cases at first presentation and are dispensable at relapse from the clinical point of view.
To investigate if VEGF mRNA levels are of clinical relevance in childhood ALL as it was suggested recently for ALL at first presentation, 12 we analyzed VEGF mRNA expression in pediatric patients suffering ALL and ALL relapse after achieving complete remission. We performed a retrospective analysis of VEGF mRNA expression in a large cohort of pediatric patients with first relapse of BCP-ALL treated uniformly according to the ALL-REZ BFM 96 protocol. And indeed, we found VEGF mRNA levels in relapse samples significantly elevated compared to the corresponding samples of first ALL presentation. Moreover, elevated VEGF mRNA levels in BM aspirates from 96 pediatric patients with first relapse of BCP-ALL were found to indicate poor prognosis as estimated by Kaplan-Meier analysis (Figure 2) . Expression of VEGF was directly associated with clinical risk groups and multivariate Cox regression analysis revealed an independent prognostic significance of VEGF expression (P ¼ 0.023).
Regarding the Kaplan-Meier analysis, it is remarkable that the major difference between the pEFS of the high and low VEGF groups occurs during the first year of treatment, suggesting an involvement of VEGF in the response to therapy. In addition, the MRD status of all patients belonging to the intermediate risk group was assessed. Those with poor molecular response (MRD positive, n ¼ 26) had 2.2-fold higher VEGF mRNA levels than those responding well to chemotherapy (MRD negative, n ¼ 25, P ¼ 0.005) ( Table 3 ). In line with these results, recent studies indicated that VEGF plays not only a role in angiogenesis, but also promotes hematopoietic cell survival. 48 VEGF inhibits apoptotic death in leukemic cells after exposure to etoposide and doxorubicin, drugs also applied in the relapse trials ALL-REZ BFM, by inducing MCL1, a member of the BCL2 family. Additionally, VEGF promotes survival of myeloid cells by induction of BCL2 expression and inhibition of apoptosis via VEGFR2. 49 Interestingly, in hematopoietic stem cells VEGF signalling is involved in regulating cell survival by an internal autocrine loop mechanism via both VEGF receptors. 47 Taken together the following conclusions can be drawn from our analysis. First, there is clear evidence for a role of HIF-1a in the BM microenvironment of highly proliferating ALL. Second, VEGF expression in the BM of ALL is weaker than that seen in BM metastases of neuroblastoma. Third, leukemic cells of relapsed ALL express more VEGF mRNA than leukemic cells of ALL at first presentation. Fourth, within relapsed ALL of childhood high VEGF mRNA levels are associated with poor prognosis and poor molecular response to chemotherapy.
